Skip to content

Intranasal fentanyl as add-on therapy in screening of retinopathy of prematurity - to reduce the pain associate with rop screening

"Intranasal fentanyl as add-on therapy in screening of retinopathy of prematurity - A double blind randomized control trial." - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055556
Enrollment
80
Registered
2023-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H36- Retinal disorders in diseases classified elsewhere

Interventions

Intervention1: Intranasal fentanyl[2µg/kg]: (breast milk to be given to child 30 minute before the screening and 0.5% proparacaine eye drop to put 1 minute before screening) standard screening proced

Sponsors

DR SANDIP KUMAR SAHU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Preterm infants heaving gestational age

Exclusion criteria

Exclusion criteria: Unstable neonates ( ventilate) and sedated neonate Neonates with C/I for fentanyl Neonates planned for surgery and neonate with congenital defects, and neurological disfunction

Design outcomes

Primary

MeasureTime frame
-To compare the effects of intranasal fentanyl (I) with standard care (C) in reducing procedural pain related to ROP screening (O) in preterm neonates (P) to be evaluated by the premature infant pain profile - R (PIPP-R) scoreTimepoint: immediately after screening,1 minute after screening,5 minute after screening

Secondary

MeasureTime frame
1. . To compare the incidences of ocular and systemic side effect in neonates(due to intra nasal fentanyl) like apneic episodes, need of respiratory support and episodes of bradycardia & desaturation between the groups 2.To compare the time taken to complete the procedure successfully in both Timepoint: patient was kept under abservation for next 24 hour to look out for any ocular and systemic,and local side effect

Countries

India

Contacts

Public ContactDr Debasish sadangi

ALL INDIA INSTUTITE OF MEDICAL SCIENCES, BHUBANESWAR

drsandipsahu@yahoo.com7978243970

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026